UPDATE: Raymond James Starts Corbus Pharmaceuticals (CRBP) at Outperform

January 19, 2018 5:03 AM EST
Get Alerts CRBP Hot Sheet
Price: $0.30 -3.23%

Rating Summary:
    4 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 6 | Down: 4 | New: 6
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - January 19, 2018 5:46 AM EST)

(updated to add analyst comment)

Raymond James initiates coverage on Corbus Pharmaceuticals (NASDAQ: CRBP) with a Outperform rating and a price target of $24.00.

ANalyst Laura Chico comments "In the three years since its IPO, Corbus Pharmaceuticals has diligently advanced its wholly-owned, lead asset lenabasum to pivotal studies in systemic sclerosis (SSc), with efforts also progressing in dermatomyositis (DM) and cystic fibrosis (CF). To date, we think data supports advancement, particularly when we consider the unmet need left by current therapies. Overall, recent non-dilutive funding from CFF and NIH provides important validation for Corbus."

For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.

Shares of Corbus Pharmaceuticals closed at $7.95 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Raymond James, IPO